Insider Trading Alert - AMSF, VRX And STKL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 1, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $311.47 to $11,658,664.23.

Highlighted Stocks Traded by Insiders:

AMERISAFE (AMSF) - FREE Research Report

Bradley C Allen Jr, who is Chairman and CEO at AMERISAFE, sold 12,212 shares at $42.75 on Dec. 1, 2014. Following this transaction, the Chairman and CEO owned 131,836 shares meaning that the stake was reduced by 8.48% with the 12,212-share transaction.

The shares most recently traded at $41.85, down $0.90, or 2.15% since the insider transaction. Historical insider transactions for AMERISAFE go as follows:

  • 4-Week # shares sold: 10,568
  • 12-Week # shares sold: 10,568
  • 24-Week # shares sold: 10,568

The average volume for AMERISAFE has been 77,400 shares per day over the past 30 days. AMERISAFE has a market cap of $804.5 million and is part of the financial sector and insurance industry. Shares are up 1.18% year-to-date as of the close of trading on Friday.

AMERISAFE, Inc., an insurance holding company, markets and underwrites workers' compensation insurance for small to mid-sized employers engaged in construction, trucking, manufacturing, oil and gas, agriculture, maritime, and logging industries. The stock currently has a dividend yield of 1.12%. The company has a P/E ratio of 14.8. Currently, there are 2 analysts who rate AMERISAFE a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMSF - FREE

TheStreet Quant Ratings rates AMERISAFE as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AMERISAFE Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Farmer Ronald Harold, who is Director at Valeant Pharmaceuticals International, bought 1,000 shares at $163.95 on Dec. 1, 2014. Following this transaction, the Director owned 32,504 shares meaning that the stake was boosted by 3.17% with the 1,000-share transaction.

The shares most recently traded at $145.81, down $18.14, or 12.44% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 2,481
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 2,481
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 2,481
  • 24-Week # shares sold: 10,000

The average volume for Valeant Pharmaceuticals International has been 2.7 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $48.6 billion and is part of the health care sector and drugs industry. Shares are up 23.89% year-to-date as of the close of trading on Friday.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. The company has a P/E ratio of 94.0. Currently, there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SunOpta (STKL) - FREE Research Report

Kendall Jeremy, who is Director at SunOpta, sold 10,000 shares at $13.50 on Dec. 1, 2014. Following this transaction, the Director owned 473,833 shares meaning that the stake was reduced by 2.07% with the 10,000-share transaction.

The shares most recently traded at $11.96, down $1.54, or 12.88% since the insider transaction. Historical insider transactions for SunOpta go as follows:

  • 4-Week # shares bought: 2,007
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 2,007
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 3,521
  • 24-Week # shares sold: 60,000

The average volume for SunOpta has been 282,900 shares per day over the past 30 days. SunOpta has a market cap of $803.8 million and is part of the consumer goods sector and food & beverage industry. Shares are up 19.78% year-to-date as of the close of trading on Friday.

SunOpta Inc. sources, processes, packages, and markets natural and organic food products in the United States, Canada, Europe, China, and Ethiopia. The company operates in two segments, SunOpta Foods and Opta Minerals. The company has a P/E ratio of 60.0. Currently, there is 1 analyst who rates SunOpta a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on STKL - FREE

TheStreet Quant Ratings rates SunOpta as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full SunOpta Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Amazon, Procter & Gamble, Southwest and Netflix - 5 Things You Must Know

Amazon, Procter & Gamble, Southwest and Netflix - 5 Things You Must Know

Oil Tests $70 as Saudi Arabia Preps Aramco IPO and Sanction Threats Bite

Oil Tests $70 as Saudi Arabia Preps Aramco IPO and Sanction Threats Bite

Amazon Spikes After Bezos Hails Prime Membership Topping 100 Million

Amazon Spikes After Bezos Hails Prime Membership Topping 100 Million

Global Stocks Mixed as Oil, Commodity Price Surges Ignite Fresh Inflation Talk

Global Stocks Mixed as Oil, Commodity Price Surges Ignite Fresh Inflation Talk

P&G Scoops Consumer Healthcare Unit From Germany's Merck in First Peltz-era Deal

P&G Scoops Consumer Healthcare Unit From Germany's Merck in First Peltz-era Deal